David Heimbrook

6.5k total citations · 2 hit papers
69 papers, 4.6k citations indexed

About

David Heimbrook is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, David Heimbrook has authored 69 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Molecular Biology, 35 papers in Oncology and 11 papers in Genetics. Recurrent topics in David Heimbrook's work include Cancer-related Molecular Pathways (19 papers), Virus-based gene therapy research (11 papers) and Ubiquitin and proteasome pathways (8 papers). David Heimbrook is often cited by papers focused on Cancer-related Molecular Pathways (19 papers), Virus-based gene therapy research (11 papers) and Ubiquitin and proteasome pathways (8 papers). David Heimbrook collaborates with scholars based in United States, Switzerland and Netherlands. David Heimbrook's co-authors include Christian Tovar, Lyubomir T. Vassilev, Allen Oliff, Kathryn Packman, Xiaolan Zhao, Kenneth Kolinsky, Stephen G. Sligar, Brian Higgins, Binh Thanh Vu and Dejan Knezevic and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

David Heimbrook

69 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1

2006 620 citations Lyubomir T. Vassilev, Christian Tovar et al. Proceedings of the National Academy of Sciences profile →
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy

2006 553 citations Christian Tovar, James Rosinski et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Heimbrook United States	34	3.0k	2.3k	609	472	397	69	4.6k
Christine Lukacs United States	21	3.9k 1.3×	2.5k 1.1×	484 0.8×	637 1.3×	315 0.8×	35	5.3k
James J. Manfredi United States	40	3.5k 1.2×	2.9k 1.3×	830 1.4×	785 1.7×	304 0.8×	79	5.3k
William N. Hait United States	38	2.8k 0.9×	2.0k 0.9×	536 0.9×	691 1.5×	233 0.6×	92	4.8k
Michael R. Mattern United States	46	5.8k 1.9×	2.6k 1.2×	416 0.7×	610 1.3×	356 0.9×	107	7.0k
Joan M. Carboni United States	34	2.4k 0.8×	1.4k 0.6×	570 0.9×	804 1.7×	216 0.5×	75	4.0k
Nader Fotouhi United States	19	3.3k 1.1×	2.3k 1.0×	388 0.6×	547 1.2×	175 0.4×	47	4.7k
Jeffrey M. Besterman United States	42	4.2k 1.4×	1.2k 0.5×	441 0.7×	291 0.6×	290 0.7×	98	5.5k
Nancy E. Kohl United States	42	5.2k 1.7×	2.4k 1.1×	820 1.3×	843 1.8×	680 1.7×	97	8.0k
Christopher L. Morton United States	45	3.2k 1.0×	1.5k 0.7×	344 0.6×	663 1.4×	475 1.2×	128	5.6k
Moulay A. Alaoui‐Jamali Canada	42	3.1k 1.0×	1.3k 0.6×	463 0.8×	792 1.7×	338 0.9×	138	4.8k

Countries citing papers authored by David Heimbrook

Since Specialization

Citations

This map shows the geographic impact of David Heimbrook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Heimbrook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Heimbrook more than expected).

Fields of papers citing papers by David Heimbrook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Heimbrook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Heimbrook. The network helps show where David Heimbrook may publish in the future.

Co-authorship network of co-authors of David Heimbrook

This figure shows the co-authorship network connecting the top 25 collaborators of David Heimbrook. A scholar is included among the top collaborators of David Heimbrook based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Heimbrook. David Heimbrook is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Higgins, Brian, Kelli Glenn, Antje‐Christine Walz, et al.. (2014). Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach. Clinical Cancer Research. 20(14). 3742–3752. 50 indexed citations

Yang, Hong, Brian Higgins, Kenneth Kolinsky, et al.. (2011). Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer. Cancer Research. 72(3). 779–789. 170 indexed citations

Wang, Huisheng, Sherif Daouti, Wenhui Li, et al.. (2011). Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-Raf V600E Mutation. Cancer Research. 71(16). 5535–5545. 62 indexed citations

He, Wei, Leopoldo Luistro, Daisy Carvajal, et al.. (2011). High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ‐secretase inhibitor, RO4929097. Molecular Oncology. 5(3). 292–301. 38 indexed citations

Daouti, Sherif, Brian Higgins, Kenneth Kolinsky, et al.. (2010). Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models. Molecular Cancer Therapeutics. 9(1). 134–144. 23 indexed citations

Yang, Hong, Brian Higgins, Kenneth Kolinsky, et al.. (2010). RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models. Cancer Research. 70(13). 5518–5527. 307 indexed citations

Tovar, Christian, Brian Higgins, Dayanand Deo, et al.. (2010). Small-molecule inducer of cancer cell polyploidy promotes apoptosis or senescence: Implications for therapy. Cell Cycle. 9(16). 3384–3395. 24 indexed citations

Daouti, Sherif, Huisheng Wang, Wenhui Li, et al.. (2009). Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy. Cancer Research. 69(5). 1924–1932. 25 indexed citations

Luistro, Leopoldo, Wei He, Melissa Smith, et al.. (2009). Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties. Cancer Research. 69(19). 7672–7680. 154 indexed citations

10.

Su, Fei, Hong Yang, Jianping Chen, et al.. (2007). Plx4032, a selective b-rafV600E inhibitor has potent anti-tumor activity in b-rafV600E-bearing colorectal xenografts and shows additive effect with other chemoagents. Molecular Cancer Therapeutics. 6. 3 indexed citations

11.

Tovar, Christian, James Rosinski, Zoran Filipovic, et al.. (2006). Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proceedings of the National Academy of Sciences. 103(6). 1888–1893. 553 indexed citations breakdown →

12.

Vassilev, Lyubomir T., Christian Tovar, Shaoqing Chen, et al.. (2006). Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proceedings of the National Academy of Sciences. 103(28). 10660–10665. 620 indexed citations breakdown →

13.

Stirdivant, Steven M., et al.. (1997). Cloning and mutagenesis of the p110α subunit of human phosphoinositide 3′-hydroxykinase. Bioorganic & Medicinal Chemistry. 5(1). 65–74. 4 indexed citations

14.

Barnett, Stanley F., et al.. (1995). Interfacial Catalysis by Phosphoinositide 3'-Hydroxykinase. Biochemistry. 34(43). 14254–14262. 13 indexed citations

15.

Huang, Pearl S., Lenora J. Davis, Hans E. Huber, et al.. (1995). An SH3 domain is required for the mitogenic activity of microinjected phospholipase C‐γ1. FEBS Letters. 358(3). 287–292. 67 indexed citations

16.

Huang, Pearl S., Denis R. Patrick, Gwynneth M. Edwards, et al.. (1993). Protein Domains Governing Interactions Between E2F, the Retinoblastoma Gene Product, and Human Papillomavirus type 16 E7 Protein. Molecular and Cellular Biology. 13(2). 953–960. 23 indexed citations

17.

Stirdivant, Steven M., Hans E. Huber, Denis R. Patrick, et al.. (1992). Human Papillomavirus Type 16 E7 Protein Inhibits DNA Binding by the Retinoblastoma Gene Product. Molecular and Cellular Biology. 12(5). 1905–1914. 2 indexed citations

18.

Heimbrook, David, Steven M. Stirdivant, Denis R. Patrick, et al.. (1991). Biological activity of a transforming growth factor-alpha-Pseudomonas exotoxin fusion protein in vitro and in vivo. Journal of Industrial Microbiology & Biotechnology. 7(3). 203–207. 2 indexed citations

19.

Saari, Walfred S., et al.. (1989). A gastrin-releasing peptide antagonist containing a ψ(CH2O) amide bond surrogate. Biochemical and Biophysical Research Communications. 165(1). 114–117. 20 indexed citations

20.

Wegrzyn, Ronald, Deborah Defeo-Jones, David Heimbrook, et al.. (1989). Spontaneously Transformed NRK Cells Lose Their Mitogenic Response to Epidermal Growth Factor. Growth Factors. 1(3). 227–236. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact